Menu
Log In Sign Up
Article

cyclic rgdfk peptide Cyclo(RGDfK) is a RGD pipetide

Published October Oct 18, 2026 4:06 AM

In the specialized field of biochemical research, the cyclic RGDfK peptide has emerged as a cornerstone for those investigating cellular interactions. As a dedicated enthusiast of peptide research, I have spent significant time examining the molecular architecture of this compound. Its unique configuration, often identified by the chemical formula $C_{27}H_{41}N_9O_7$ and a molecular weight of 603.7 g/mol, provides a fascinating look into the precision of synthetic chemistry.

Molecular Precision and Characteristics

The cyclic RGDfK is not merely a sequence; it is a meticulously engineered molecule. Known in laboratory settings as cyclo(Arg-Gly-Asp-D-Phe-Lys), it contains an Arg-Gly-Asp (RGD) sequence that is essential for its biological activity. My observations in reviewing high-purity samples—often exceeding 98% or 99% HPLC purity—confirm that the stability of this cyclic peptide is largely due to its rigid ring structure.

When discussing the chemical structure of the synthetic cyclic RGD peptide c(RGDfK), it is vital to note how the D-phenylalanine (f) and lysine (K) residues contribute to its selective binding properties. Cyclo(-RGDfK) is a cyclic peptide that demonstrates exceptional binding affinity, which makes it a preferred tool for researchers exploring receptor-ligand dynamics.

Research Applications and Integrin Binding

One of the most compelling aspects of this compound is that it is a well-validated ligand for targeting active to Cyclo(-RGDfK) | Chemical | CAS 161552-03-0 integrin αvβ3. In my experience with various biochemical assays, the precision with which this molecule interacts with specific cell surfaces is remarkable.

* αvβ3 Integrin Inhibit Cyclic Peptide Antibiotics Guide ion: Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, often showing IC50 values as low as 0.94 nM.

* Targeted Delivery: The versatility of the molecule is evident in studies where cRGDfK peptide-conjugated succinoyl-TPGS nanomicelles h 作者:G Mondal·2013·被引用次数:57—We show that a lipopeptide containing widely acclaimed αvβ3 integrin receptor selectivecyclic RGDfKligand in its head-group area can effectively deliver  ave been utilized, showcasing how researchers leverage its targeting capabilities.

* Cellular Interaction: Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells under controlled experimental conditions, primarily through its specific binding affinity.

Comparative Insights

While Cyclo(-RGDfK) rema The integrin alpha(IIb)beta(3)-specific cyclic hexapeptidecontains an Arg-Gly-Asp (RGD) sequence. Sequence, Cyclo(-RGDfK). Sequence (3 Letter), Cyclo(-Arg-Gly  ins a primary focus, there are variations such as Cyclo(-RGDfC), which serves as another high-purity integrin-binding peptide. Whether one is utilizing cyclic RGDfK or exploring the broader category o Cyclo(-RGDfK) is a cyclic peptidesand a highly effective and selective Integrin αvβ3 inhibitor with an IC50 value of 0.94 nM. It specifically binds to the  f cyclic RGD peptide (cRGD), the fundamental goal remains the same: understanding how these synthetic molecules mimic natural binding motifs.

It is 作者:H Kulhari·2015·被引用次数:69—We report the synthesis ofcRGDfK peptide-conjugated succinoyl-TPGS(tocopheryl polyethylene glycol succinate) nanomicelles for targeted delivery of DTX. also worth noting that Cyclo(RGDfK) is a synthetic lipopeptide inhibitor of αvβ3 integrin, a designation that highlights its utility in complex biochemical environments. Researchers frequently cite that it effectively targets tumor microvessels and cancer cells, making it a staple in advanced laboratory protocols.

Concluding Observations

As someone deeply interested in the evolution of peptide tools, I find that the Cyclic RGDFK peptide continues to offer reliable performance in qualitative studies. Whether it is identified as a cyclic RGD tumor-targeting peptide or simply a RGD peptide, its role in modern research is undeniable. The reproduci Cyclic Peptides as Therapeutic Agents and Biochemical Tools - PMC bility of results—provided the compound is sourced with high purity—is a testament to the rigorous standards now applied to the synthesis of these cyclic peptides.

By maintaining a focus on the structural integrity and the specific binding kinetics of RGDfK, researchers can continue to push the boundaries of what is possible in biochemical investigation, ensuring that every experiment is grounded in verifiable, high-quality data.

Leave a Comment
Get new articles in your inbox

News, updates and freebies. No spam, unsubscribe anytime.